Dr Intae Lee with the University of Pennsylvania presented the pre-clinical in vivo data at the American Society for Therapeutic Radiology and Oncology (ASTRO) 49th Annual Meeting in Los Angeles. During his presentation, Dr Lee and his team of researchers identified non-invasive imaging biomarkers that can potentially be used as a therapeutic predictor for Onconase in non-small cell lung cancer patients.
Onconase reduced the tumor hypertension that is the major physiological barrier of therapeutic delivery to solid tumors and increased tumor penetration and selectively increased tumor blood flow.
Kuslima Shogen, Alfacell’s chairman and CEO, said: “We are pleased to see that through continuing research we are learning about the broader potential for Onconase. Biomarkers are important in assessing patients’ responses to treatments, and the reduction of lactate levels in response to Onconase is a positive indication of its possible utility.”